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PURPOSE: The epithelial–mesenchymal transition (EMT) plays a key role in breast cancer progression and 
metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate 
the clinicopathological significance of LCN2 expression in breast cancer. 
METHODS: The expression of LCN2 protein was immunohistochemically assessed in two well-characterised 
annotated cohorts of breast cancer (discovery cohort, n = 612; validation cohort, n = 1,363). The relationship of 
LCN2 expression and subcellular location with the clinicopathological factors and outcomes of patients was 
analysed. 
RESULTS: Absent or reduced nuclear LCN2 expression was associated with features of aggressive behaviour, 
including high histological grade, high Nottingham Prognostic Index, high Ki67 labelling index, hormone 
receptor negativity and human epidermal growth factor receptor 2 positivity. The high cytoplasmic expression of 
LCN2 was correlated with lymph node positivity. The nuclear downregulation of LCN2 was correlated with the 
overexpression of EMT associated proteins (N-cadherin and Twist-related protein 2) and basal biomarkers 
(cytokeratin 5/6 and epidermal growth factor receptor). Unlike the cytoplasmic expression of LCN2, the loss of 
nuclear expression was a significant predictor of poor outcome. The combinatorial expression tumours with 
high cytoplasmic and low nuclear expression were associated with the worst prognosis. 
CONCLUSIONS: Tumour cell expression of LCN2 plays a role in breast cancer progression with loss of its 
nuclear expression is associated with aggressive features and poor outcome. Further functional analysis is 
warranted to confirm the relationship between the subcellular localisation LCN2 and behaviour of breast cancer. 
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INTRODUCTION 
Breast cancer is a heterogeneous disease with variable morphology, metastatic behaviour and response to 
therapy [1]. Further investigations of new biomarkers are warranted to develop a personalised management of 
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this disease. Lipocalin 2 (LCN2) is a secreted glycoprotein that transports small lipophilic ligands and acts as an 
iron binding protein. It also acts as a member of the autocrine system via SLC22A17 (receptor of LCN2) in 
cancer cells [2-4]. LCN2 is expressed in the extracellular matrix of tumours, regulates the epithelial–
mesenchymal transition (EMT), and is involved in the proliferation of cancer cells [5, 6]. Previous studies 
suggested that LCN2 expressed in stromal tissue may regulate tumour angiogenesis, oncogenesis and 
progression in various types of cancer by controlling EMT and proliferation [7, 8]. LCN2 has been associated 
with matrix metallopeptidase 9 (MMP9), which is an established factor related to EMT and tumour metastasis in 
the extracellular matrix [9]. When LCN2 forms a complex with MMP9, it increases MMP9-activity and 
prevents its auto-degradation. Since MMP9 degrades the extracellular matrix and basement membranes, LCN2/
MMP9 complex contributes to tumour progression, invasion and metastasis [9]. 
Abnormal expression of LCN2 plays important role in various pathological conditions including inflammation 
and tissue injury. LCN2 is also considered as a potential biomarker and a modulator of human epithelial 
malignancy. The expression of LCN2 is dysregulated in a variety of cancers including hepatocellular [8], 
pancreatic [10], colorectal [11], and prostate [12] carcinomas. In the breast, it has been reported that stroma-
secreted LCN2 promotes metastasis in vitro and in vivo and contributes to tumour progression [13]. Decreasing 
LCN2 expression has reduced the invasion and migration ability of HER2-positive breast cancer cells [14]. 
However, some authors have reported that overexpression of LCN2 does not affect cell proliferation or 
anchorage-independent growth in vitro, or primary tumor weight in vivo [15]. Data from The Cancer Genome 
Atlas (TCGA) using 1,075 cases indicates an association between loss of LCN2 mRNA expression and poor 
prognosis [16]. Therefore, clinicopathological significance of LCN2 expression and its morphological 
characteristics a in breast cancer remain unclear. In the present study, we attempt to demonstrate the 
clinicopathological significance of LCN2 expression using immunohistochemistry (IHC). We assessed the 
relationship between LCN2 expression and its subcellular localisation and other clinicopathological factors, 
including breast cancer progression/metastasis-related biomarkers and breast cancer patient outcomes. 
MATERIALS AND METHODS 
Patients` characteristics 
Two independent cohorts of patients with early invasive breast cancer were included in this study: a discovery 
set and a validation set comprising 612 and 1,363 patients, respectively. The clinicopathological significance of 
the nuclear, cytoplasmic and combined expression of LCN2 was evaluated using the former set. The 
clinicopathological and prognostic value of the nuclear expression of LCN2 was further validated using the 
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latter set. All patients underwent primary breast surgery without prior neoadjuvant therapy at the Nottingham 
University Hospitals (Nottingham, UK). Clinical and pathological data of patients (i.e. age at diagnosis, 
histological tumour type, grade, tumour size, lymph node status, Nottingham Prognostic Index and 
lymphovascular invasion) were collected. Survival data, including breast cancer-specific survival (BCSS; 
defined as the time [in months] from the date of the primary surgical treatment to the time of death from breast 
cancer), were retrieved. Data related to the expression of basic breast cancer markers, including oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2), are available [17-19]. 
The expression of a large panel of breast cancer progression/metastasis-related biomarkers, including the Ki67 
labelling index, E-cadherin, N-cadherin, P-cadherin, Twist-related protein 2 (TWIST2) and basal markers 
(cytokeratin 5/6 [CK5/6] and epidermal growth factor receptor [EGFR]), was also studied in a previous IHC 
analysis using the discovery cohort [20-25]. 
Immunohistochemistry 
The specificity of the LCN2 antibody (LS-C405956; Lifespan Biosciences, Seattle, WA) (dilution: 1:500) was 
validated, and a specific band (70 kDa) was detected through western blotting of lysate obtained from the cell 
line HeLa (The American Type Culture Collection, Rockville, MD) (Supplementary Fig 1). Full-face tissue 
sections from patients with invasive breast cancer (n = 10) [24-26] were stained before tissue microarray (TMA) 
to assess the morphological characteristics of LCN2 expression and test the suitability of this method. TMA 
sections from the discovery and validation sets were IHC-stained to evaluate the expression of LCN2 protein. 
The H-score [27, 28] was used to assess the nuclear and cytoplasmic expression of LCN2. 
Statistical analysis 
SPSS statistical software version 24.0 (IBM Corp., Armonk, NY) was used for statistical analysis. The χ2 and 
Fisher’s exact tests were used to evaluate the relationships between LCN2 expression and clinicopathological 
factors. BCSS was used to assess the prognostic utility of LCN2 expression. The association with survival was 
evaluated using the Kaplan–Meier method and the log-rank test. Multivariate survival analyse was assessed 
using the Cox proportional hazards regression model. The median of the H-scores was used as a cutoff point to 
divide the samples into high- and low-LCN2 expression groups. A p-value <0.05 (two-tailed) denoted statistical 
significance. 
RESULTS 
Morphological characteristics of LCN2 protein expression 
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The morphological features of LCN2 expression using full-face tissue sections of invasive breast cancer are 
shown in Figure 1. LCN2 showed staining signals in both the cytoplasm and nucleus of malignant epithelial 
cells, with weak staining noted in the stroma. The expression of LCN2 in the nuclei of adjacent apparently 
normal terminal duct-lobular units was moderate to strong. In contrast, the LCN2 nuclear immunoreactivity of 
invasive cancer cells was lower than that of adjacent normal epithelial cells. The immunoreactivity of LCN2 in 
the cytoplasm of cancer cells was moderate compared with that reported in the nucleus. 
In this study, 310 (51%) cases showed high cytoplasmic expression whereas 316 (52%) cases showed high 
nuclear expression.  Regarding subcellular localisation, cases were classified into four combinatorial phenotypic 
groups as follows: (1) low nuclear and high cytoplasmic expression (21%); (2) high nuclear and low 
cytoplasmic expression (19%); (3) both with low expression (30%); and (4) both with high expression (29%) 
(Fig 2). 
Clinicopathological characteristics of LCN2 protein expression 
The low nuclear expression of LCN2 was significantly associated with high histological grade (p < 0.0001), 
high Nottingham Prognostic Index (p = 0.00055), ER negativity (p < 0.0001), PR negativity (p = 0.0013) and 
breast cancer subtypes (p = 0.00034) (Table 1). A total of 60% of HER2-positive and 65% of triple-negative 
cases showed a low nuclear expression of LCN2. Low nuclear expression was significantly associated with high 
Ki67 labelling index (p < 0.0001), high N-cadherin expression (p = 0.00052), high TWIST2 expression (p = 
0.039), CK5/6 positivity (p = 0.0088) and EGFR positivity (p = 0.019). However, no correlation was identified 
between the nuclear expression of LCN2 and E-cadherin (Table 2). In addition, the low nuclear expression of 
LCN2 was associated with a shorter BCSS (X2 = 4.90, p = 0.027) (Fig 3a). 
The high cytoplasmic expression of LCN2 was significantly correlated with lymph node metastasis (p = 0.039; 
Table 1) and expression of E-cadherin (p = 0.010; Table 2). However, the cytoplasmic expression of LCN2 was 
not a significant predictor of outcome (Supplementary Fig 2). 
Validation analysis for the clinicopathological significance of LCN2 nuclear expression 
In the validation cohort, the low nuclear expression of LCN2 was significantly associated with high histological 
grade (p < 0.0001), high Nottingham Prognostic Index (p < 0.0001), ER negativity (p < 0.0001) and PR 
negativity (p < 0.0001). The downregulation of the nuclear expression of LCN2 was also significantly related to 
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large tumour size (p = 0.00066) and HER2 positivity (p = 0.0042; Supplementary Table 1). A total of 75% of 
triple-negative cases showed a low nuclear expression of LCN2 (p < 0.0001) (Supplementary Table 1).  
The significance of the low nuclear expression of LCN2 as a poor prognostic marker was validated in 1,363 
cases (χ2 = 11.66, p = 0.00064) (Fig 3b), although the low nuclear expression of LCN2 was not an independent 
prognostic marker in the multivariate analysis (Supplementary Table 2)   
Combinatorial expression 
Although no significant difference in the survival between these four groups, the tumours with low cytoplasmic 
and high nuclear expression showed the best outcome whereas the tumours with high cytoplasmic and low 
nuclear expression showed the worst outcome (Supplementary Fig 3).  
DISCUSSION 
EMT plays a key role in the metastasis of breast cancer [29]. Several previous studies have indicated the 
possible value of biomarkers associated with EMT as prognostic factors and have proposed their utility in 
predicting the response of invasive breast cancer to chemotherapy [30, 31]. In the present study, a low nuclear 
expression of LCN2 was significantly associated with a high expression of N-cadherin and TWIST2. N-
cadherin, a member of the genetically related transmembrane glycoproteins, promotes tumour–stroma 
interactions and stimulates cell motility, invasion and metastasis [32, 33]. The overexpression of TWIST2 
promotes metastasis of breast cancer by activating EMT and enhancing the self-renewal system of cancer stem-
like cells [34]. Previous studies have suggested that LCN2 regulates the activity of the Ras pathway and 
regulates cell migration and EMT [35, 36]. Further functional studies are necessary to explore the association of 
aberrant LCN2 function with EMT in invasive breast cancer. 
In the present study, the low nuclear expression of LCN2 was significantly associated with the positive 
expression of basal markers such as CK5/6 and EGFR. Several studies have suggested a strong correlation 
between the expression of basal cytokeratins and cell proliferation [37, 38]. EGFR is not a basal-like specific 
marker like CK5/6; however, it is expressed in the basal-like type and strongly assists in the 
immunohistochemical identification of this type [39, 40]. The Nottingham Prognostic Index+ is based on the 
assessment of the biological class combined with established clinicopathological prognostic variables, including 
CK5/6 and EGFR. This index provides improved stratification of patient outcomes for invasive breast cancer 
[41]. Recently, the use of molecular-targeted therapy against EGFR-positive breast cancer (e.g. neratinib [42], 
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pertuzumab [43] and lapatinib [44]) has been proposed. The association of LCN2 expression with basal-like 
breast cancers may define a subset of patients more likely to benefit from treatment with these agents. 
Several previous studies investigating the complex role of LCN2 in a variety of cancer types have suggested that 
LCN2 leads to apoptosis and suppresses proliferation/metastasis [8, 10, 45, 46]; however, a number of other 
studies have suggested that the expression of LCN2 promotes tumour growth, migration and invasion [47, 48]. 
The low nuclear expression of LCN2 has been significantly related to high tumour proliferation, hormonal 
receptor negativity, HER2 positivity and poor prognostic outcome. Notably, other studies have indicated that the 
high cytoplasmic expression of LCN2 is associated with the decreased disease-free survival in patients with 
invasive breast cancer [49, 50]. In the present study, the cytoplasmic expression of LCN2 was related to 
positivity for lymph node metastasis. The tumour microenvironment controls the LCN2-autocrine system of 
cancer cells via endoplasmic reticulum stress-dependent and -independent mechanisms [51]. Once released in 
the extracellular compartment, LCN2 drives iron sequestration and internalisation through established receptors, 
promoting cell survival and EMT [48, 51]. These mechanisms may be responsible for the clinicopathologically 
significant discrepancy observed between the nuclear and cytoplasmic expression of LCN2. Therefore, further 
investigations are warranted to examine the activity and functions of LCN2 based on its intracellular 
localisation. 
CONCLUSIONS 
Not only the expression but also subcellular localisation of LCN2 expression appears to play a role in breast 
cancer progression. Loss or reduced expression of nuclear LCN2 expression is related to the aggressive types 
and poor outcome in breast cancer. Further functional studies of LCN2 in breast cancer with consideration of its 
subcellular localisation in tumour cells are warranted. 
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FIGURE LEGENDS 
Fig. 1 Immunohistochemical analysis of the morphological characteristics of LCN2 
 (a) The normal terminal duct-lobular unit showed a high immunoreactivity of LCN2 in the nuclei 
(magnification: ×200). (b) The expression of LCN2 in the stromal cells was weak (magnification: ×100). (c) The 
nuclear immunoactivity of LCN2 in invasive breast cancer cells was weaker than that observed in normal 
epithelial cells. However, the cytoplasmic immunoreactivity of LCN2 in invasive breast cancer cells was 
moderate (magnification: ×200). 
Fig. 2 Representative tissue microarray images of the expression of LCN2 
(a) Low nuclear and low cytoplasmic expression of LCN2; (b) low nuclear and high cytoplasmic expression of 
LCN2; (c) high nuclear and low cytoplasmic expression of LCN2; and (d) high nuclear and high cytoplasmic 
expression of LCN2. Magnification: ×200 for all images. 
Fig. 3 Breast cancer-specific survival stratified according to the nuclear expression of LCN2 
 (a) In the discovery cohort, breast cancer-specific survival was significantly worse in the LCN2-low expression 
group versus the LCN2-high expression group. (b) For the validation cohort, a significant difference was 
observed in the breast cancer-specific survival between LCN2-high and -low expression tumours.
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Table 1 Associations between LCN2 nuclear/cytoplasmic expression and clinicopathological features 
Factors
Nuclear expression Cytoplasmic expression
 High LCN2 Low LCN2
p-value
 High LCN2 Low LCN2
p-value
N (%) N (%) N (%) N (%)
Tumour size
˂2.0 cm 150 (52.3%) 137 (47.7%)
0.075
147 (51.2%) 140 (48.8%)
0.81
≥2.0 cm 146 (44.9%) 179 (55.1%) 163 (50.2%) 140 (48.8%)
Nodal status
Negative 181 (48.8%) 190 (51.2%)
0.80
175 (47.2%) 196 (52.8%)
0.039
Positive 115 (47.7%) 126 (52.3%) 135 (56.0%) 106 (44.0%)
Nottingham Prognostic Index
Good prognostic group 109 (60.2%) 72 (39.8%)
0.00055
89 (49.2%) 92 (50.8%)
0.21Moderate prognostic group 149 (44.3%) 187 (55.7%) 165 (49.1%) 171 (50.9%)
Poor prognostic group 38 (40.0%) 57 (60.0%) 56 (58.9%) 39 (41.1%)
Histological grade
Grades 1 and 2 189 (58.7%) 133 (41.3%)
<0.0001
156 (48.4%) 166 (51.6%)
0.26
Grade 3 107 (36.9%) 183 (63.1%) 154 (53.1%) 136 (46.9%)
Lymphovascular invasion
Negative 174 (50.9%) 168 (49.1%)
0.17
170 (49.7%) 172 (50.3%)
0.63
Positive 122 (45.2%) 148 (54.8%) 140 (51.9%) 130 (48.1%)
Oestrogen receptor (ER)
Negative 49 (33.6%) 97 (66.4%)
<0.0001
74 (50.7%) 72 (49.3%)
1.00
Positive 247 (53.0%) 219 (47.0%)
<0.0001
236 (50.6%) 230 (49.4%)
1.00
Progesterone receptor (PR)
Negative 99 (40.2%) 147 (59.8%)
0.0013
116 (47.2%) 130 (52.8%)
0.16
Positive 197 (53.8%) 169 (46.2%) 194 (53.0%) 172 (47.0%)
Human epidermal growth factor receptor 2 (HER2)
Negative 260 (49.9%) 261 (50.1%)
0.070
267 (51.2%) 254 (48.8%)
0.50
Positive 36 (39.6%) 55 (60.4%) 43 (47.3%) 48 (52.7%)
Breast cancer subtypes
ER- and/or PR-positive/HER2-negative 223 (53.9%) 191 (46.1%)
0.00034
216 (52.2%) 198 (47.8%)
0.55HER2-positive 36 (39.6%) 55 (60.4%) 43 (47.3%) 48 (52.7%)
Triple negative 37 (34.6%) 70 (65.4%) 51 (47.7%) 56 (52.3%)
Table 2 Association of LCN2 nuclear/cytoplasmic expression with the expression of breast cancer progression/metastasis-related biomarkers 
Factors
Nuclear expression Cytoplasmic expression
 High LCN2 Low LCN2
p-value
 High LCN2 Low LCN2
p-value
N (%) N (%) N (%) N (%)
Ki67 labelling index
Low (<10%) 110 (59.5%) 75 (40.5%)
<0.0001
93 (50.3%) 92 (49.7%)
0.93
High (>10%) 114 (40.1%) 170 (59.9%) 145 (51.1%) 139 (48.9%)
E-cadherin
Low 150 (45.3%) 181 (54.7%)
0.099
151 (45.6%) 180 (54.4%)
0.010
High 135 (52.3%) 126 (47.7%) 149 (56.4%) 115 (43.6%)
N-cadherin
Low 83 (60.6%) 54 (39.4%)
0.00052
75 (54.7%) 62 (45.3%)
0.48
High 140 (42.7%) 188 (57.3%) 167 (50.9%) 161 (49.1%)
P-cadherin
Low 117 (43.7%) 151 (56.3%)
0.66
137 (51.1%) 131 (48.9%)
0.79
High 109 (45.8%) 129 (54.2%) 125 (52.5%) 113 (47.5%)
TGF-β
Low 92 (44.4%) 115 (55.6%)
1.00
100 (48.3%) 107 (51.7%)
0.21
High 134 (44.8%) 165 (55.2%) 162 (54.2%) 137 (45.8%)
TWIST2
Low 106 (58.6%) 75 (41.4%)
0.039
97 (53.6%) 84 (46.4%)
0.92
High 118 (48.2%) 127 (51.8%) 129 (52.7%) 116 (47.3%)
CK5/6
Negative 257 (51.1%) 246 (48.9%)
0.0088
256 (50.9%) 247 (49.1%)
1.00
Positive 37 (36.6%) 64 (63.4%) 51 (50.5%) 50 (49.5%)
EGFR
Negative 245 (51.0%) 235 (49.0%)
0.019
248 (51.7%) 232 (48.3%)
0.61
Positive 47 (38.8%) 74 (61.2%) 59 (48.8%) 62 (51.2%)
Supplementary Table 2 Survival analysis based on clinicopathological characteristics of breast cancer, including LCN2 nuclear expression 
Factors
Multivariate analysis 
Hazard Ratio 95% CI p value
LCN2 nuclear expression
Low Reference
High 0.88 0.68-1.15 0.36
Tumour size
< 2cm Reference
> 2cm 1.38 1.05-1.79 0.018
Nodal status
Negative Reference
Positive 2.11 1.79-2.48 <0.0001
Histological grade
Low Reference
High 1.91 1.51-2.41 <0.0001
Supplementary Table 1 Associations between LCN2 nuclear expression and clinicopathological features in the validation set 
Factors
 High LCN2 (nuclear) Low LCN2 (nuclear)
p-value
N (%) N (%)
Tumour size
˂2.0 cm 404 (49.9%) 406 (50.1%)
0.00066
≥2.0 cm 217 (40.3%) 321 (59.7%)
Nodal status
Negative 397 (48.2%) 427 (51.8%)
0.052
Positive 222 (42.6%) 299 (57.4%)
Nottingham Prognostic Index
Good prognostic group 266 (61.4%) 167 (38.6%)
<0.0001Moderate prognostic group 283 (41.5%) 399 (58.5%)
Poor prognostic group 70 (46.1%) 159 (69.4%)
Histological grade
Grades 1 and 2 427 (59.2%) 294 (40.8%)
<0.0001
Grade 3 194 (30.9%) 433 (69.1%)
Lymphovascular invasion
Negative 455 (47.7%) 498 (52.3%)
0.063
Positive 166 (42.0%) 229 (58.0%)
Oestrogen receptor
Negative 69 (24.4%) 214 (75.6%)
<0.0001
Positive 553 (51.8%) 514 (48.2%)
Supplementary Table 2 Survival analysis based on clinicopathological characteristics of breast cancer, including LCN2 nuclear expression 
Factors
Multivariate analysis 
Hazard Ratio 95% CI p value
LCN2 nuclear expression
Low Reference
High 0.88 0.68-1.15 0.36
Tumour size
< 2cm Reference
> 2cm 1.38 1.05-1.79 0.018
Nodal status
Negative Reference
Positive 2.11 1.79-2.48 <0.0001
Histological grade
Low Reference
High 1.91 1.51-2.41 <0.0001
Progesterone receptor
Negative 201 (35.7%) 362 (64.3%)
<0.0001
Positive 417 (53.6%) 361 (46.4%)
Human epidermal growth factor receptor 2
Negative 555 (47.6%) 610 (52.4%)
0.0042
Positive 67 (36.2%) 118 (63.8%)
Breast cancer subtypes
Triple negative 53 (25.5%) 155 (74.5%)
<0.0001
Non-triple negative 569 (49.8%) 573 (50.2%)








